NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System

Clinical Toxicology

Volumn 53, Issue 7, 2015, Pages 624-628

  Srisuma, Sahaphume ^a,b   Bronstein, Alvin C ^a   Hoyte, Christopher O ^a,c  

^a ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

2C; NBOMe; Substitute phenylethylamine

Indexed keywords

2,5 DIMETHOXY PHENYLETHYLAMINE; BENZODIAZEPINE; BENZYL DERIVATIVE; CREATINE KINASE; DESIGNER DRUG; INFUSION FLUID; N 2 METHOXYBENZYL; PHENETHYLAMINE DERIVATIVE; PSYCHEDELIC AGENT; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE;

ACIDOSIS; ADOLESCENT; ADULT; AGITATION; ARTICLE; CHRONICITY; CLINICAL FEATURE; CONFUSION; CREATINE KINASE BLOOD LEVEL; DELUSION; DIAPHORESIS; DROWSINESS; ENVIRONMENTAL EXPOSURE; FEMALE; HALLUCINATION; HUMAN; HYPERTENSION; HYPERTHERMIA; INGESTION; INHALATION; INTENSIVE CARE; INTUBATION; IRRITABILITY; KIDNEY FAILURE; LETHARGY; MALE; MYDRIASIS; NORMAL HUMAN; OXYGEN THERAPY; POISON CENTER; SEIZURE; TACHYCARDIA; VOMITING; YOUNG ADULT; CHEMICALLY INDUCED; HALLUCINATIONS; INCIDENCE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANIMALIA;

ADOLESCENT; BENZODIAZEPINES; DESIGNER DRUGS; FEMALE; HALLUCINATIONS; HUMANS; INCIDENCE; MALE; PHENETHYLAMINES; POISON CONTROL CENTERS; RETROSPECTIVE STUDIES; TACHYCARDIA; UNITED STATES; YOUNG ADULT;

EID: 84938597576     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2015.1054502     Document Type: Article

References (10)

1. Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 2013;9:172-178.
2. Lawn W, Barratt M, Williams M, Horne A, Winstock A. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 2014;28:780-8.
3. Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol 2015;53:85-92.
4. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 2006;70:1956-1964.
5. Bronstein AC, Spyker DA, Cantilena LR, Green JL, Rumack BH, Giffin SL. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol 2009;47:911-1084.
6. Forrester MB. 2C series phenethylamine derivative exposures in Texas. Subst Abuse 2013;34:81-82.
7. Forrester MB. NBOMe designer drug exposures reported to Texas poison centers. J Addict Dis 2014;33:196-201.
8. Yin S, Ho M. Monitoring a toxicological outbreak using Internet search query data. Clin Toxicol 2012;50:818-822.
9. Hanson CL, Cannon B, Burton S, Giraud-Carrier C. An exploration of social circles and prescription drug abuse through Twitter. J Med Internet Res 2013;15:e189.
10. Halberstadt AL, Geyer MA. Effects of the hallucinogen 2,5-dimethoxy- 4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 2014;77:200-7.